← Companies|Maplewood Bio
Ma

Maplewood Bio

Cambridge MAFounded 202120 employees
Private CapbiotechPrivateOncology
Platform: Targeted TPD
Market Cap
N/A
All Drugs
4
Clinical Trials
8
Failed / Terminated
1
FDA Approved
1
Drug Pipeline (4 programs)
Drug NameCodePhaseTrialsModalityTargetMOAIndications
FixatapinarofMAP-8538Phase 22siRNAUSP1IL-17iDLBCLSchizophrenia
MAP-6526MAP-6526Approved3mRNAPD-1MeniniACCNMOSD
ElratapinarofMAP-3327Preclinical2RadioligandNectin-4JAK1iGastric Ca
SemacageneMAP-1226Phase 1/21Gene EditingSGLT2TROP-2 ADCNBOCD
Financial Documents
This is a private company — SEC filings are not available.
Catalyst Events (8)
2025-07-04
Elratapinarof Conference
Gastric Ca
Past
2026-05-18
MAP-6526 Ph1 Dose Esc
Heart Failure
Ph1 Dose Esc
2027-06-26
MAP-6526 Ph3 Readout
Heart Failure
Ph3 Readout
2028-03-17
MAP-6526 Ph3 Readout
NMOSD
Ph3 Readout
2028-04-20
Fixatapinarof Ph2 Data
Schizophrenia
Ph2 Data
2028-05-04
MAP-6526 Ph3 Readout
ACC
Ph3 Readout
2030-01-15
Elratapinarof Interim
Gastric Ca
Interim
2030-10-06
Fixatapinarof Ph2 Data
Schizophrenia
Ph2 Data